JP Morgan Chase
MAZE

JP Morgan Chase’s Maze Therapeutics MAZE Stock Holding History

JP Morgan Chase’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,000
Closed -$609K – 8190
2026
Q1 		$609K Buy
+21,000
New +$927K ﹤0.01% 4879

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

JP Morgan Chase's MAZE Position: Q2 2026 in Review

JP Morgan Chase increased its Maze Therapeutics (MAZE) stake by 1,549% in Q2 2026, buying an estimated $23.7M and bringing the position to 964,011 shares worth $28M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

JP Morgan Chase first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • JP Morgan Chase held 964,011 shares of Maze Therapeutics worth $28M as of Q2 2026.
  • JP Morgan Chase bought 905,565 Maze Therapeutics shares in Q2 2026, an estimated $23.7M.
  • Maze Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1938 holding.
  • JP Morgan Chase first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.